Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Tournai – page 126

1 811 clinical trials in Tournai, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tournai at a glance
1 811
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 811 trials in Tournai

Open in trial search

Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant+3

Not recruiting

Study of ALX148, Pembrolizumab, and Chemotherapy for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evorpacept
  • Sponsor:Alx Oncology Holdings Inc.

Study on Setanaxib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Calliditas Therapeutics Suisse S.A.

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Huntington's disease

Not recruiting

Study on the Safety and Efficacy of Tominersen for Patients with Prodromal and Early Manifest Huntington's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Tominersen
  • Sponsor:F. Hoffmann-La Roche AG

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Novartis Pharma AG

Non-Hodgkin's lymphoma+13

Not recruiting

Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tazemetostat
  • Sponsor:Epizyme Inc.

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Hepatitis alcoholic

Not recruiting

Study on the Effects of INT-787 for Patients with Severe Alcohol-Associated Hepatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:INT-787
  • Sponsor:Intercept Pharmaceuticals Inc.

Ischaemic stroke

Not recruiting

Study on Glenzocimab for Patients with Large Ischemic Stroke Eligible for Endovascular Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Tournai

What the registry says about research in the country

01 Inflammatory Bowel Disease Research

Comprehensive studies focusing on Crohn's disease and ulcerative colitis treatments, evaluating new therapeutic approaches for patients with moderate to severe conditions.

  • Novel therapeutic agents evaluation
  • Post-operative disease management
  • Long-term treatment effectiveness

Multiple trials are investigating innovative medications including obefazimod and mirikizumab for improved patient outcomes.

02 Gastrointestinal Disorders

Groundbreaking research into eosinophilic esophagitis treatment options, examining the efficacy of new medications for reducing inflammation and improving symptoms.

  • Tissue inflammation reduction
  • Dysphagia symptom management
  • Long-term safety studies

Current trials are evaluating solrikitug as a potential treatment option for patients with EoE.

03 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and estrogen receptor-positive cases in elderly patients.

  • Genomic-guided therapy
  • Adjuvant treatment optimization
  • HPV infection management

Studies are exploring personalized treatment approaches combining chemotherapy and hormone therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.